Class Action Lawsuit Announced Against Atara Biotherapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 29 2026
0mins
Should l Buy ATRA?
Source: PRnewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, alleging that the company made false and misleading statements during this period, potentially leading to investor losses.
- Compensation Mechanism: Investors participating in the class action will not incur any out-of-pocket expenses, as the law firm will operate on a contingency fee basis, ensuring that investors do not bear additional financial burdens during the legal process.
- Legal Representation Advisory: The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record, noting that many firms issuing notices may lack the necessary experience and resources, urging investors to be cautious in their choice of legal representation.
- Impact Analysis: The lawsuit claims that Atara faced manufacturing and clinical trial issues that could jeopardize FDA approval of its biologics license application, likely resulting in significant negative impacts on the company's financial condition, prompting investors to monitor developments closely to assess potential losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.900
Low
18.00
Averages
21.50
High
25.00
Current: 4.900
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which resulted in significant financial losses for investors and damaged the company's reputation and market confidence.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success rather than those acting merely as intermediaries, ensuring effective legal support and representation in the litigation.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Choosing Legal Counsel: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel to effectively protect investor rights, advising against firms that merely act as intermediaries without substantial litigation experience.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities in securities litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. is facing allegations for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, which undermines investor confidence due to misleading positive statements about the company's prospects.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. is accused of not disclosing manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially overstating the likelihood of FDA approval for its product, which could significantly impact the company's financial condition.
- Coty Legal Issues: Coty Inc. is under scrutiny for failing to reveal underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, leading to misleading positive statements about its business operations and prospects, which may affect investor trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to reach out for legal rights discussions, emphasizing the firm's commitment to protecting investor interests.
See More
Faruqi & Faruqi Investigates Atara Securities Litigation
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against Atara Biotherapeutics, particularly for investors who purchased securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- FDA Response Letter Impact: On January 12, 2026, Atara received a Complete Response Letter from the FDA stating that its EBVALLO™ Biologics License Application was not approved, causing the stock price to plummet by 56.99% to $5.88 per share, reflecting market pessimism about its future prospects.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by May 22, 2026, with Faruq & Faruq emphasizing the importance of this deadline to protect investors' legal rights.
- Potential Impact Assessment: The lawsuit alleges that Atara and its executives violated federal securities laws by failing to disclose manufacturing issues and clinical trial deficiencies, which could significantly harm the company's financial condition and operations, further exacerbating investor loss risks.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating significant legal risks for the company.
- Regulatory Scrutiny: On January 16, 2025, Atara received a Complete Response Letter from the FDA regarding its tabelecleucel BLA, resulting in a 40.5% drop in stock price, highlighting serious compliance issues that could hinder future financing and erode market confidence.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's Investigational New Drug applications due to GMP compliance issues identified during inspections, exacerbating investor concerns about the company's future and causing a further 7.91% decline in stock price.
- Severe Market Reaction: Following another Complete Response Letter from the FDA on January 12, 2026, Atara's stock plummeted by 56.99%, reflecting a drastic loss of investor confidence in the company's product development prospects, which may lead to capital withdrawal and impact long-term strategic plans.
See More
Atara Biotherapeutics Faces Class Action for Misleading Investors
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact stock price and market confidence.
- FDA Regulatory Risks: The lawsuit alleges that Atara misled investors regarding the regulatory prospects of its lead drug candidate, tabelecleucel, due to manufacturing issues and deficiencies in the ALLELE study, which could prevent FDA approval of its Biologics License Application (BLA), significantly affecting the company's financial condition.
- Stock Price Plunge: On January 12, 2026, Atara announced that the FDA issued another Complete Response Letter (CRL) regarding the tabelecleucel BLA, causing the stock price to plummet by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, and even those who choose not to participate can still be eligible for recovery, providing investors with a potential avenue for legal recourse.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which resulted in significant financial losses for investors and damaged the company's reputation and market confidence.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success rather than those acting merely as intermediaries, ensuring effective legal support and representation in the litigation.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Choosing Legal Counsel: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel to effectively protect investor rights, advising against firms that merely act as intermediaries without substantial litigation experience.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, demonstrating its strong capabilities in securities litigation.
See More
Multiple Companies Face Class Action Lawsuits
- Lufax Class Action: Lufax Holding Ltd. is facing allegations for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, which undermines investor confidence due to misleading positive statements about the company's prospects.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. is accused of not disclosing manufacturing issues and clinical trial risks from May 20, 2024, to January 9, 2026, potentially overstating the likelihood of FDA approval for its product, which could significantly impact the company's financial condition.
- Coty Legal Issues: Coty Inc. is under scrutiny for failing to reveal underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, leading to misleading positive statements about its business operations and prospects, which may affect investor trust.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to reach out for legal rights discussions, emphasizing the firm's commitment to protecting investor interests.
See More
Faruqi & Faruqi Investigates Atara Securities Litigation
- Legal Investigation Initiated: Faruq & Faruq LLP is investigating potential claims against Atara Biotherapeutics, particularly for investors who purchased securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- FDA Response Letter Impact: On January 12, 2026, Atara received a Complete Response Letter from the FDA stating that its EBVALLO™ Biologics License Application was not approved, causing the stock price to plummet by 56.99% to $5.88 per share, reflecting market pessimism about its future prospects.
- Litigation Deadline Reminder: Investors must apply to be lead plaintiffs in the federal securities class action by May 22, 2026, with Faruq & Faruq emphasizing the importance of this deadline to protect investors' legal rights.
- Potential Impact Assessment: The lawsuit alleges that Atara and its executives violated federal securities laws by failing to disclose manufacturing issues and clinical trial deficiencies, which could significantly harm the company's financial condition and operations, further exacerbating investor loss risks.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California, representing investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws, indicating significant legal risks for the company.
- Regulatory Scrutiny: On January 16, 2025, Atara received a Complete Response Letter from the FDA regarding its tabelecleucel BLA, resulting in a 40.5% drop in stock price, highlighting serious compliance issues that could hinder future financing and erode market confidence.
- Clinical Trials Halted: The FDA placed a clinical hold on Atara's Investigational New Drug applications due to GMP compliance issues identified during inspections, exacerbating investor concerns about the company's future and causing a further 7.91% decline in stock price.
- Severe Market Reaction: Following another Complete Response Letter from the FDA on January 12, 2026, Atara's stock plummeted by 56.99%, reflecting a drastic loss of investor confidence in the company's product development prospects, which may lead to capital withdrawal and impact long-term strategic plans.
See More
Atara Biotherapeutics Faces Class Action for Misleading Investors
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact stock price and market confidence.
- FDA Regulatory Risks: The lawsuit alleges that Atara misled investors regarding the regulatory prospects of its lead drug candidate, tabelecleucel, due to manufacturing issues and deficiencies in the ALLELE study, which could prevent FDA approval of its Biologics License Application (BLA), significantly affecting the company's financial condition.
- Stock Price Plunge: On January 12, 2026, Atara announced that the FDA issued another Complete Response Letter (CRL) regarding the tabelecleucel BLA, causing the stock price to plummet by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future.
- Shareholder Action Guidance: Shareholders can submit their papers by May 22, 2026, to serve as lead plaintiffs in the class action, and even those who choose not to participate can still be eligible for recovery, providing investors with a potential avenue for legal recourse.
See More
